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ABSTRACT
Objective: To investigate the impact on mortality due
to pneumonia or influenza of the change from risk-
based to age group-based targeting of the elderly for
yearly influenza vaccination in England and Wales.
Design: Excess mortality estimated using time series
of deaths registered to pneumonia or influenza,
accounting for seasonality, trend and artefacts. Non-
excess mortality plotted as proxy for long-term trend in
mortality.
Setting: England and Wales.
Participants: Persons aged 65–74 and 75+ years
whose deaths were registered to underlying pneumonia
or influenza between 1975/1976 and 2004/2005.
Outcome measures: Multiplicative effect on average
excess pneumonia and influenza deaths each winter in
the 4–6 winters since age group-based targeting of
vaccination was introduced (in persons aged 75+ years
from 1998/1999; in persons aged 65+ years from
2000/2001), estimated using multivariable regression
adjusted for temperature, antigenic drift and vaccine
mismatch, and stratified by dominant circulating
influenza subtype. Trend in baseline weekly pneumonia
and influenza death rates.
Results: There is a suggestion of lower average
excess mortality in the six winters after age group-
based targeting began compared to before, but the CI
for the 65–74 years age group includes no difference.
Trend in baseline pneumonia and influenza mortality
shows an apparent downward turning point around
2000 for the 65–74 years age group and from the
mid-1990s in the 75+ years age group.
Conclusions: There is weakly supportive evidence
that the marked increases in vaccine coverage
accompanying the switch from risk-based to age
group-based targeting of the elderly for yearly influenza
vaccination in England and Wales were associated with
lower levels of pneumonia and influenza mortality in
older people in the first 6 years after age group-based
targeting began. The possible impact of these policy
changes is observed as weak evidence for lower
average excess mortality as well as a turning point in
baseline mortality coincident with the changes.
INTRODUCTION
There has been no assessment of the impact
on mortality of the switch from risk-based to
age group-based targeting of yearly inﬂuenza
vaccination of the elderly in England and
Wales. The policy of targeting people for
yearly inﬂuenza vaccination based on risk
alone, in place until 1998/1999, meant that
only people with certain medical conditions
(chronic heart, respiratory or renal disease,
diabetes mellitus or immunosuppression)
were offered free yearly inﬂuenza vaccin-
ation.1 The age group-based targeting policies
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adopted in 1998–2000 meant that from then on, all those
people aged 75 years and over (from 1998) and aged
65 years and over (from 2000) would be offered free
yearly inﬂuenza vaccination. These policy changes were
followed by a marked increase in vaccination coverage of
those aged 65 years and over, from 46% in the winter of
1999/2000 to 66% in 2000/2001 (calculated based on
reported coverage in high-risk and low-risk people aged
65+ years in [2]). Vaccine coverage has continued to rise
or stay above this level ever since.2–4 Evidence for lower
excess mortality due to pneumonia or inﬂuenza (P&I) in
the elderly in the years shortly following the move to age
group-based targeting, or for a fall in baseline respiratory
mortality in the elderly coincident with these policy
changes, would be evidence that these changes have pre-
vented more elderly deaths than the former risk-based
approach to vaccine targeting.
Debate surrounds the question of the efﬁcacy and
effectiveness of inﬂuenza vaccine in the elderly.5–8 Two
systematic reviews concluded that there is insufﬁcient
good quality evidence,9 10 though one of these reviews
did include a randomised controlled trial showing efﬁ-
cacy against inﬂuenza disease of 58% (95% CI 26% to
77%) in adults aged 60 years and over.11 Observational
studies controlling for positive confounding by healthier
people seeking vaccination have also demonstrated
effectiveness against mortality.12 13 There has been
much interest in measuring the mortality impact of
inﬂuenza vaccination of the elderly in other settings and
the results have been mixed. In Holland, all-cause excess
mortality during inﬂuenza epidemics declined after the
introduction of universal yearly vaccination of those
aged 65 years and over.14 In contrast, three other
studies, in the USA, Italy and Catalonia, did not detect
an impact of rising vaccine coverage of the elderly on
all-cause excess mortality.15–17 Previous studies of inﬂu-
enza attributable or excess mortality in the UK have not
related this to vaccination.18–20
While the level of mortality observed when inﬂuenza
is circulating in the community (often quantiﬁed using
excess mortality) varies from winter to winter, baseline
respiratory mortality (ie, excluding excess) has a sea-
sonal pattern which is more or less constant from winter
to winter, though it may change over the long term.21
Previous studies of the long-term trends in
inﬂuenza-related mortality in England and Wales have
covered earlier, and usually shorter, time periods. One
study examined trends in P&I mortality in England and
Wales from 1994/1995 to 2000/2001 and showed a plot
of rates of P&I mortality in the 65–74 years age group in
this period, which appears to have little secular trend.18
The shape of the trend in baseline respiratory mortality
in England and Wales since 2000/2001 is unclear.
This work evaluates a public health initiative to specif-
ically target all people aged 65 years and older for yearly
inﬂuenza vaccination regardless of their risk group,
which has been in place since 2000. Studying patterns in
excess mortality and trends in baseline mortality in the
years shortly following the introduction of this initiative
allows us to provide evidence for the impact of this
policy.
METHODS
Daily counts of deaths registered to underlying P&I in
England and Wales between 1975 and 2005, by date of
death, sex and age group, were provided by the Ofﬁce
for National Statistics (ONS). Deaths registered to
underlying P&I, not just conﬁrmed inﬂuenza deaths,
were analysed because deaths from inﬂuenza are rarely
laboratory conﬁrmed and because deaths in the elderly,
which occur secondary to inﬂuenza, often result from
pneumonia.22 23 P&I mortality rates are a more speciﬁc
measure of inﬂuenza activity than rates of all-cause
mortality.24
The mortality data were adjusted by multiplying them
by conversion factors estimated in a separate analysis to
account for the following historical modiﬁcations to how
the data are coded so that our assessment of trends
would not be inﬂuenced by these artefactual step
changes. The International Classiﬁcation of Diseases
(ICD) changed from V.8 to V.9 in 1979, leading to a small
decline in deaths coded to underlying P&I.25 In 1984,
ONS introduced a broader interpretation of rule 3 for
coding the underlying cause of death, which led to an
abrupt fall in deaths registered to underlying pneumonia,
and to a rise in deaths registered to underlying cancer
and ischaemic heart disease.26 In 1993, ONS adopted an
automated system for coding the underlying cause of
death, which narrowed the interpretation of rule 3 and
approximately reversed the change adopted in 1984 (ie,
rates of deaths being registered to underlying pneumonia
rose back to a level approximately equal to that
pre-1984).27 With the change from ICD 9 to ICD 10 in
2000, deaths coded to underlying respiratory disease fell
by approximately 22%, and deaths coded speciﬁcally to
underlying pneumonia fell by 38%.28
The Health Protection Agency Centre for Infections
(HPA CfI) provided an extract of all individual reports
of laboratory-conﬁrmed inﬂuenza A infections between
1975 and 2005 from their LabBase2 database. These
reports, based on virus isolation and PCR, were reported
voluntarily by the National Health Service (NHS) and
HPA laboratories in England and Wales. Records
included individuals’ age, sex and the earliest specimen
date.
The statistical methods used are summarised below, with
full details provided in online supplementary material.
Vaccine coverage estimates for 1989/1990–2004/2005
were adapted from published sources. Published estimates
of vaccine coverage were available by age group and separ-
ately for persons considered at high or low risk of inﬂu-
enza complications.2 3 Separate estimates by risk group
were combined proportionately according to the number
of each group vaccinated to give coverage for that age
group regardless of the risk group.
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There are numerous approaches in the literature to
quantifying excess mortality as a measure of inﬂuenza
severity but no gold standard approach. We elected to
modify the method of Simonsen et al,15 used in their
paper analysing inﬂuenza vaccine impact in the USA, to
examine excess mortality as well as the long-term trend
in non-excess mortality in relation to changes in vaccine
policy and coverage. The Simonsen method is a modiﬁ-
cation of Serﬂing’s cyclical regression approach,21 where
non-epidemic data are modelled to estimate expected
mortality and mortality greater than expected is labelled
as excess, but improves on the speciﬁcity of Serﬂing’s
model in that epidemic periods in the data are informed
by a speciﬁc measure of inﬂuenza.
An inﬂuenza year was deﬁned as week 26 of a given
year to week 25 of the next year because the timing of
inﬂuenza circulation during a given winter usually spans
two calendar years (ie, extends from October of a given
year to March of the next year). Mortality and laboratory
data were collapsed into weekly counts for analysis. In
order to differentiate excess from baseline mortality, we
used laboratory data to estimate which were the epi-
demic weeks in the time series. We then ﬁtted models to
the mortality time series to determine excess as well as
baseline mortality with reference to these epidemic
weeks. Excess mortality was the sum of observed minus
predicted deaths in weeks when laboratory data brea-
ched their epidemic threshold, by inﬂuenza year.
Baseline trend in mortality incidence was approximated
by ﬁtting the mortality model to the death counts not
labelled as excess. This model ﬁt was then deconstructed
and just the spline (ie, trend) component was plotted in
order to graphically assess its shape for changes, or
turning points, in the direction of the trend coincident
with policy changes. In the same way, estimates of excess
mortality were plotted over time to look for evidence of
turning points in the trend. Estimates of excess mortality
and plots of baseline trends were determined separately
for the age groups 65–74, 75+ and 45–64 years (the
latter age group being ‘unexposed’ to a change in
vaccine policy or coverage over the period). Any esti-
mates of negative excess mortality were recoded to 0. No
model was stratiﬁed by sex because an initial exploration
of the data suggested similar trends by sex in the study
period. A sensitivity analysis was carried out deﬁning epi-
demic periods based on counts of combined laboratory-
conﬁrmed inﬂuenza A and B virus infections (as
opposed to the main analysis where this was performed
using counts of inﬂuenza A infections only).
To quantify vaccine impact on excess mortality, we ﬁtted
age group-speciﬁc regression models of excess mortality
for each inﬂuenza year against (1) a dummy variable
having a value of 0 for 1989/1990–1999/2000 and 1 for
2000/2001–2004/2005 to capture the start of the policy
targeting all those aged 65+ years for yearly inﬂuenza vac-
cination (exposure of interest), (2) the minimum monthly
temperature observed in each inﬂuenza year,29 (3)
whether the inﬂuenza season experienced a large
antigenic drift event or not30 and (4) whether the inﬂu-
enza season was characterised by a mismatch between
vaccine and circulating H3N2 viruses or not (from the lit-
erature). Excess deaths are right skewed and hence were
transformed using log(excess + 1) to obtain a good
approximation to normality. Models were ﬁtted separately
for the inﬂuenza A/H3N2 virus-dominated inﬂuenza
seasons and for the inﬂuenza seasons dominated by other
inﬂuenza virus subtypes. This was performed to allow for
greater mortality, and thus potentially greater vaccine
impact, in inﬂuenza seasons dominated by inﬂuenza
A/H3N2 viruses than those dominated by inﬂuenza
A/H1N1 or B viruses.31 Vaccine mismatch was not
included in models where the outcome was excess mortal-
ity in the non-inﬂuenza A/H3N2 virus-dominated seasons
because both mismatch seasons were those in which inﬂu-
enza A/H3N2 viruses dominated. Separate sensitivity ana-
lyses were carried out (1) deﬁning the vaccine coverage
dummy variable with reference to 1998/1999 rather than
2000/2001 (because 1998/1999 was the ﬁrst inﬂuenza
year of age group-based targeting of vaccination (to those
aged 75+ years)) and (2) modelling vaccination as a linear
term, using derived estimates of coverage by age group in
each inﬂuenza year, rather than as a dummy variable.
To establish the extent of circulation of inﬂuenza in
the community over the inﬂuenza years studied, weekly
rates of consultation for inﬂuenza-like illness (ILI), and
for infectious and parasitic diseases (which excludes
ILI), with sentinel general practices in England and
Wales for 0–4 and 5–14 year-olds were plotted over time
(data provided by the Royal College of General
Practitioners weekly returns service). We also plotted the
weekly all-age rates of laboratory-reported inﬂuenza
A and B infections over time.
Models were ﬁtted in R (R V.2.12.1 (2010-12-16),
Copyright 2010 the R Foundation for Statistical
Computing).
RESULTS
Weekly deaths registered to underlying P&I in those aged
65 years and older in England and Wales in the period
from 1975/1976 to 2004/2005 ranged from 34 deaths/
1 000 000 person-weeks (in week 36 of 1984) to 481
deaths/1 000 000 person-weeks (in week 7 of 1976).
Excess mortality
Excess mortality for the 65–74 years age group ranged
from 0 to just over 2000 deaths per inﬂuenza year in the
study period (table 1; table includes citations32–52 for
the covariates whose values were drawn from the litera-
ture). For the 75+ years age group, the range was from
0 to over 14 000 deaths/inﬂuenza-year. Mortality attribut-
able to epidemic inﬂuenza was highly variable from year
to year. For neither age group does there appear to have
been a turning point in the trend in excess mortality
coinciding with the 2000/2001 season, when the policy
of targeting all persons aged 65 years and over for yearly
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Table 1 Influenza seasons in England and Wales, 1974/1975–2004/2005: dominant variant, antigenic drift events in evoluation of influenza A/H3N2 viruses, vaccine
mismatch, vaccine coverage and numbers of excess P&I deaths by age group
Influenza
season
Dominant
influenza
variant(s)
Antigenic
drift events30
Vaccine
cluster*
Minimum
monthly
temperature
(°C)
Vaccine
coverage,
65–74 years (%)
Excess
deaths (n),
65–74 years
Vaccine
coverage,
75+ years (%)
Excess
deaths (n),
75+ years
Vaccine
coverage,
45–64 years (%)
Excess
deaths (n),
45–64 years
1975/1976 H3N2/B32 EN72-VI75 4.5 0 1910 0 9389 0 863
1976/1977 H3N233 2 0 456 0 2986 0 203
1977/1978 H3N2/H1N132 VI75-TX77 2.8 0 419 0 2563 0 158
1978/1979 B32 −0.4 0 14 0 25 0 0
1979/1980 H3N232 TX77-BA79 2.3 0 0 0 95 0 0
1980/1981 H1N1/H3N232 3 0 89 0 605 0 73
1981/1982 B/H3N234 0.3 0 174 0 501 0 4
1982/1983 H3N234 1.7 0 264 0 1947 0 48
1983/1984 H1N1/B34 3.3 0 88 0 742 0 38
1984/1985 H3N2/B34 0.8 0 74 0 395 0 5
1985/1986 B35 −1.1 0 0 0 0 0 14
1986/1987 H1N135 0.8 0 0 0 0 0 0
1987/1988 H3N2/H1N136 BA79-SI87 4.9 0 0 0 5 0 4
1988/1989 H1N1/H3N236 5.2 0 374 0 2023 0 119
1989/1990 H3N236 SI87-BE89 SI8737 4.9 22 2007 27 14115 9 638
1990/1991 B36 BE8938 1.5 24 0 31 178 9 0
1991/1992 H3N236 BE8939 3.7 27 413 33 3302 10 111
1992/1993 B/H1N136 BE89-BE92 BE8940 3.6 26 0 33 0 10 0
1993/1994 H3N236 BE9241 3.2 32 557 39 4238 12 137
1994/1995 B36 BE9242 4.8 33 0 40 0 12 0
1995/1996 H3N236 BE92-WU95 BE9243 2.3 33 651 42 5365 12 226
1996/1997 H3N236 WU9544 2.5 33 0 41 15 12 9
1997/1998 H3N2/H1N145 WU95-SY97 WU9545 5.2 38 0 46 9 14 10
1998/1999 H3N2/B46 SY9746 5.3 37 628 49 6802 13 233
1999/2000 H3N247 SY9747 4.9 40 1083 53 10554 14 560
2000/2001 B/H1N148 SY9748 3.2 59† 0 74† 109 16 0
2001/2002 H3N2/H1N249 SY9749 3.6 61† 21 76† 0 17 0
2002/2003 B/H3N250 SY97-FU02 SY9750 3.9 63† 0 78† 0 17 10
2003/2004 H3N251 SY9751 4.8 65† 338 82† 2704 18 152
2004/2005 H3N252 FU0252 4.3 64† 1 81† 27 NA 9
*Italics indicate a mismatch between a vaccine and a dominant circulating A/H3N2-virus cluster.
†Estimated from coverage 65+ years and mean ratio of coverage in the 65–74 to 65+ years age group and the 75+ to 65+ years age group for 1989/1990–1999/2000.
NA, not applicable; P&I, pneumonia or influenza.
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inﬂuenza vaccination was enacted (ﬁgure 1). Similarly,
there was no turning point in the trend in excess mortal-
ity in the 75+ years age group around 1998/1999 when
this age group became fully targeted for yearly inﬂuenza
vaccination. The direction of the trend in excess mortal-
ity over the whole time period appears to be downwards
or ﬂat. The trend in excess mortality in the 45–64 years
age group is approximately ﬂat in the same period (see
online supplementary ﬁgure S1). Mean excess mortality
was lower after the policy change for the age groups 65–
74 as well as 75+ years, but was also lower after 2000/
2001 than before among the 45–64 year-olds (see online
supplementary table S2).
Vaccine impact from multivariable regression
The point estimates for the multiplicative effect that the
policy change had on excess mortality after 2000 com-
pared to before, adjusting for cold weather and anti-
genic drift in inﬂuenza A/H3N2 viruses and stratiﬁed by
the dominant circulating virus subtype, are in the direc-
tion of lower excess mortality after 2000 than before for
the 65–74 and 75+ years age groups, except for mortality
in the seasons dominated by inﬂuenza A/H1N1 or B
viruses for the 75+ years age group for which the coefﬁ-
cient suggested higher mortality after the policy change
but with a very wide CI (ﬁgure 2). Point estimates indi-
cate a modest impact in the inﬂuenza A/H3N2 virus-
dominated seasons, which is unlikely to be due to
chance for the 75+ years age group, while in seasons
dominated by inﬂuenza A/H1N1 or B viruses the CIs
are wide and include no effect. These ﬁndings are
robust to modelling the vaccine policy change as occur-
ring in 1998/1999 instead of 2000/2001 (data not
shown). For the 45–64 years age group, the point esti-
mates suggest lower excess mortality after 2000 than
before for seasons dominated by inﬂuenza A/H3N2
viruses (ﬁgure 2). For each of the three age groups,
modelling the effect of change in vaccine coverage as a
linear instead of a binary (dummy) variable results in
the point estimates suggesting a lower excess mortality
per unit increase in vaccine coverage but with wide CIs
including the null (data not shown).
Trends in baseline mortality
Long-term trends in mortality not labelled as excess,
analysed as a proxy for baseline P&I mortality, are
complex, with three to four periods during which differ-
ent trends were observed. For the 65–74 years age
Figure 1 Excess mortality in the age groups (A) 65–74 and (B) 75+ years in each influenza season in England and Wales,
stratified by the dominant influenza virus in circulation (black ‘x’=A/H3N2 viruses were dominant or codominant; grey ‘+’=A/H1N1 or
B viruses were dominant). Vaccine coverage in the respective age group from published data is also shown (dots and asterisks,
right axis). Asterisks indicate that vaccine coverage in these years was inferred from observed vaccine coverage in the 65+ years
age group and the average ratio of coverage in the age group 65+ to 65–74 years (or 75+ years). P&I, pneumonia or influenza.
Figure 2 Summary of estimated vaccine impact from log
(excess +1) regression models of the binary effect of the
switch to age group-based targeting of yearly influenza
vaccination on all those aged 65 years and older (from 2000/
2001 onwards) compared to before 2000/2001. Coefficients
are shown on the original scale and are therefore
multiplicative. Squares, circles and triangles indicate the age
groups 65–74, 75+ and 45–64 years, respectively. Filled
symbols represent seasons dominated by influenza A/H3N2
viruses and open symbols indicate seasons dominated by
influenza A/H1N1 or B viruses.
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group, rates in the study period were highest until the
late 1970s, declined until approximately 1990, plateaued
until 2000 and fell after 2000 (ﬁgure 3). For the 75+
years age group, rates increased until the late 1970s,
declined until the mid-1980s, plateaued until the
mid-1990s and then fell. The 45–64 years age group
showed a broadly similar baseline trend to that of the
65–74 years age group, though the trend was more tortu-
ous due to smaller numbers (see online supplementary
ﬁgure S2). Residuals from ﬁtted models were normally
distributed with the mean approximately 0 and SD
approximately 1 with some residual autocorrelation
(data not shown). Findings are robust to deﬁning epi-
demic periods using laboratory reports of the inﬂuenza
A infections alone or to using the inﬂuenza A and B
infections for this purpose.
Secular trends in circulation of influenza in the community
during the study period
During the period 2000–2005, ILI consultation rates for
0–4 and 5–14 year-olds were lower than the historical
ones (see online supplementary ﬁgure S3). However,
over the same time period, consultations for infectious
and parasitic diseases (which excludes ILI) also
appeared to decline, especially in the 5–14 years age
group (see online supplementary ﬁgure S4). Rates of
laboratory reported inﬂuenza infections were lower in
2000–2005 than in the previous decade (see online sup-
plementary ﬁgure S5). Rates in 2000–2005 were similar
to those observed around 1980 (ﬁgure 3).
DISCUSSION
Statement of principal findings
There is weakly supportive evidence that the switch from
risk-based to age group-based targeting of inﬂuenza vac-
cination for older people was associated with a lower
inﬂuenza-related mortality in the 4–6 years following this
policy change. Results from our multivariable regression
suggest that this policy change had a weak, positive
impact on excess mortality in the 65–74 as well as 75+
years age groups. There is no indication of a downward
turning point in the trend in excess mortality around
2000/2001 (when all those 65+ years began to be tar-
geted for vaccination) or 1998/1999 (when those 75+
years began to be targeted). There were fewer excess
Figure 3 Model fit: the observed time series of weekly pneumonia or influenza (P&I) deaths in the age groups (A) 65–74 years
and (B) 75+ years in England and Wales between 1975 and 2005 (light dotted line on each plot). The fitted curve from the
log-linear Simonsen-like model fitted excluding December to April and accounting for seasonality, long-term trend and artefacts is
overlaid (dark line). Vaccine coverage (in the age groups 65–74 and 75+ years) adapted from published data is shown on the
right axis of each plot (dots and asterisks). Asterisks indicate that the vaccine coverage in these years was inferred from the
observed vaccine coverage in the 65+ years age group and the average ratio of coverage in the 65–74 (or 75+) to 65+ years age
group. The fitted curve can be deconstructed into its constituent parts. Thus, (C) and (D) showing the long-term trend (ie, cubic
spline) component of the fitted curve (dark lines), with its 95% CI (light lines), for the 65–74 and 75+ years age groups,
respectively. This allows a better visualisation of the shape of the long-term trend. P&I, pneumonia or influenza.
6 Mann AG, Mangtani P, Russell CA, et al. BMJ Open 2013;3:e002743. doi:10.1136/bmjopen-2013-002743
Open Access
 group.bmj.com on August 6, 2013 - Published by bmjopen.bmj.comDownloaded from 
deaths, on average, in the seasons after the policy
change than before (including in the 45–64 years age
group), which argues against a strong, speciﬁc impact of
the policy change on excess mortality. Trends in base-
line, as opposed to excess, mortality do show a sugges-
tion of a downward turning point in the mid-1990s for
the 75+ years age group and around 2000 for the
65–74 years age group, coinciding approximately with
the timing of the changes to speciﬁcally target these age
groups for vaccination. Results obtained by ﬁtting the
various models to data for the 45–64 years age group, in
whom vaccine coverage was largely static over the study
period, are in a similar direction but are of a smaller
magnitude than the apparent impact in the 65–74 and
75+ years age groups, suggesting that there may have
been other factors acting to bring down P&I mortality at
the time of the policy changes. Thus, our analysis is con-
sistent with a small mortality impact in the 65–74 and
75+ years age groups during the 6 years after policies to
wholly target these age groups for yearly inﬂuenza vac-
cination were enacted.
Strengths and weaknesses of the study
There are a number of strengths to the work under-
taken, as well as several limitations. The key strengths
are that we estimated excess mortality and long-term
trend in mortality over a long period (30 years). We care-
fully controlled for changes to death coding and labora-
tory practices which occurred over this time period. The
analytical approach we used, which is similar to the one
used by many others,15 16 of modelling seasonality and
trend using splines in addition to sinusoidal terms (full
details provided in online supplementary material), is a
highly ﬂexible method of ﬁtting complex patterns and
trends that is especially helpful when modelling a long
time series. The outcome we chose to model (deaths
from underlying P&I) is the most speciﬁc option avail-
able which allows sufﬁcient numbers of deaths for ana-
lysis. This choice maximised our ability to discern high
mortality impact inﬂuenza years from those less so, and
thus to detect vaccine impact. Analysing underlying P&I
of course means that our estimates of excess mortality
underestimate the burden of mortality due to all respira-
tory disease (which includes bronchitis), cardiovascular
disease and other causes of death which may be linked
to inﬂuenza.19 20 However, it was not the aim of this
work to estimate the total mortality burden due to inﬂu-
enza. Further adding to the speciﬁcity of our outcome
was our designation of epidemic periods in the mortality
data with reference to the time series of laboratory-
conﬁrmed inﬂuenza A infections. A still better approach
might have been to use inﬂuenza A/H3N2 infections,
the subtype most often associated with inﬂuenza years
when there is substantial mortality,53 but the laboratory
data available for this analysis were not broken down by
subtype. The limitations of our work include the follow-
ing: that our estimate of the extent of variability in
excess mortality across inﬂuenza years is likely to be an
underestimate because our model failed to explain all
variability in the mortality data (as evidenced by a small
amount of autocorrelation in residuals, data not shown).
This may be because we did not include temperature or
other climatic variables in the models estimating excess
mortality. We did adjust for temperature in multivariable
regression models of vaccine impact on excess mortality
and, as such, our analysis of vaccine impact should not
be confounded by temperature. However, our results
regarding long-term trends in non-excess mortality may
be confounded by temperature as there is evidence that
minimum winter temperatures have increased since the
early 1960s.54 In using laboratory data to inform epi-
demic periods in the mortality data, we made no allow-
ance for a lag between the increase, or peak, in
incidence of laboratory-reported infections and the
timing of excess deaths associated with these infections.
This is likely to have led us to underestimate excess mor-
tality, assuming that the peak in deaths rarely precedes
and generally coincides with or follows the peak in
laboratory reports. However, the rise in inﬂuenza activity
in the community in terms of general practitioner (GP)
consultations generally coincides with the rise in
numbers of laboratory reports of inﬂuenza infections,36
and, during inﬂuenza years dominated by circulation of
inﬂuenza A viruses, peak weekly GP consultation rates
for ILI in the 45–64, 65–74 and ≥75 years age groups
tend to coincide with same age peaks in respiratory
deaths, plus or minus 1 week (eg, 1995/1996, 1996/
1997, 1998/1999 and 1999/2000).18 Hence, the poten-
tial bias in our estimates of excess mortality is likely to
be minimal because the weeks we might have missed by
not allowing for a lag will be close to the start or end of
the period of inﬂuenza circulation and thus will make
up a small proportion of the total inﬂuenza attributable
P&I deaths in a given winter. Our estimates of long-term
trends may be confounded by the trends in comorbid-
ities linked to smoking or by the long-term patterns in
other comorbidities associated with respiratory mortality,
which we have not accounted for. While it would have
been possible to test for a change in slope of the long-
term trend with a piecewise linear approximation, we
did not do this because issues of confounding by these
types of time-varying covariates, which we are only able
to speculate about, would limit the interpretability of
any coefﬁcient. Finally, the separate vaccine coverage
estimates that we present for the 65–74 and 75+ years
age groups from 2000/2001 onwards are sensitive to our
assumption of a constant ratio of vaccine coverage in the
65–74 and 75+ years age groups from 2000/2001
onwards (described in online supplementary ﬁle). The
assumption of a constant ratio is unlikely to be true and,
as such, we have probably underestimated coverage in
the 65–74 years age group and overestimated it in the
75+ years age group; the increase in coverage in 2000/
2001 was probably disproportionately accounted for by
an increase in coverage in the 65–74 years age group,
newly targeted as fully ‘at risk’ from the 2000/2001
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inﬂuenza season. Our main ﬁndings are unaffected by
this because we focus on the results from regression
models of the effect of change in vaccination policy as a
binary variable.
Strengths and weaknesses in relation to other studies,
discussing important differences in results
Using as a reference the previous estimates which exist
of excess respiratory mortality in England and Wales,
our estimates appear to be a valid reﬂection of variability
between years and between age groups in
inﬂuenza-attributable mortality. Findings as to the
vaccine impact from other settings have been mixed;
thus, our observation of perhaps some limited impact is
not inconsistent with reports from other settings which
analysed the impact of similar levels of vaccine coverage
to that achieved in the UK. Previous estimates of excess
all-age respiratory mortality for the inﬂuenza years
1975/1976, 1976/1977 and 1977/1978 are higher than
our excess P&I estimates for these years, but the relative
magnitude of the excess mortality between these years
matches our estimates well (see online supplementary
table S1). The absolute value of the previous estimates is
higher than ours because the authors included bron-
chitis deaths and analysed all ages combined, not just
the elderly. For the inﬂuenza years 1994/1995–1999/
2000, published estimates of average inﬂuenza-
attributable respiratory mortality by age group (45–64,
65–74 and 75+ years) are higher than our averages for
the same age groups over the same period, but ratios
between different age groups are similar to our esti-
mates. Differences in the magnitude of estimates from
the two methods will be not only because they include
bronchitis deaths but also because the rate difference-
type method used by Fleming and colleagues tends to
produce higher estimates of excess than the
Serﬂing-type method we used, due to a lower reference
mortality and the mortality rate in the ‘inﬂuenza-active
periods’ being entirely attributed to inﬂuenza.55 There
has been much interest in measuring the impact of
inﬂuenza vaccination campaigns in other settings.14 15 17 56
Excess all-cause mortality declined in the Dutch elderly
after the introduction of universal yearly vaccination of
those aged 65 years and over, which saw yearly coverage
reach 80%.14 Excess all-cause mortality and inﬂuenza-
related hospitalisations and GP visits declined more in
Ontario than in other Canadian provinces after the
introduction of universal yearly vaccination for all
Ontario residents.56 Analyses of the impact of rising
vaccine coverage of the elderly on excess all-cause mor-
tality in the USA, Italy and Catalonia did not detect
impact perhaps because, in the case of the USA and
Italy, the coverage did not reach high enough levels for
long enough during the study period, or because, as in
Catalonia, there were limited data available, prior to
coverage exceeding 60%, to provide a baseline against
which to estimate impact.15–17 Because the ratios of our
estimates of excess P&I between adjacent seasons, and
between age groups, are consistent with previous work
using different models, we are conﬁdent that our
impression of the relative magnitude of P&I mortality
between age groups and from one inﬂuenza year to the
next year are a true reﬂection of patterns in inﬂuenza
mortality during the study period. Our observation of
some evidence for vaccine impact on excess mortality in
the 6 years after implementation of age group-based
inﬂuenza vaccination is consistent with the ﬁndings
from other temperate northern hemisphere settings
which have attained similar levels of vaccine coverage in
the elderly, where some studies have demonstrated an
impact and others have not.
Meaning of the study: possible explanations and
implications for clinicians and policymakers
Our analysis suggests that high yearly vaccination cover-
age of the elderly had a small impact on P&I deaths in
the 4–6 years following implementation of age group-
based targeting of the elderly for inﬂuenza vaccination.
Alternative explanations are that there was less inﬂuenza
around during the time of high vaccine coverage,
making it look like vaccination produced an impact on
mortality when it did not. The fact that we observed
smaller magnitude but same direction associations
between the timing of policy changes in the elderly and
mortality in the 45–64 years age group, in whom vaccin-
ation policy and coverage were approximately constant
over the study period, supports this alternative explan-
ation. However, our analysis of the extent to which inﬂu-
enza circulated in the community in the study period
does not provide clear answers: consultations among
children for both ILI as well as infectious and parasitic
diseases (which excludes respiratory disease) were lower
in the 2000–2005 period than earlier in the study
period. It is difﬁcult to interpret lower ILI rates as strong
evidence for less inﬂuenza circulating in 2000–2005
than previously since the decline in rates of infectious
and parasitic diseases rates then still needs explaining. It
may in part be that there was progressively lower use of
GP services in the 2000–2005 period. Rates of
laboratory-reported inﬂuenza infections for all ages
reported to HPA CfI were certainly lower in 2000–2005
than in the previous decade, and were similar to the
rates observed around 1980 when excess mortality also
appeared to be low for several consecutive years. It is dif-
ﬁcult to interpret the long-term trends in laboratory
reports of inﬂuenza infections because of the changing
testing practices and changing volumes of test requisi-
tions over the time period. For example, between 1975
and 1992, the number of laboratory reports of viral
infections doubled57; this is unlikely to reﬂect a doub-
ling of viral infections over this period. If more tests
were requisitioned in 2000–2005 than in the years
around 1980, similar rates of positive reports in the two
periods would suggest less viral activity in 2000–2005
than around 1980. However, it is hard to see how less
inﬂuenza in circulation later than earlier in the study
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period could explain a turning point in baseline mortal-
ity in the 65–74 and 75+ years age groups approximately
coincident with policy changes to speciﬁcally target
these age groups for vaccination. We think the observa-
tion of a turning point in baseline mortality reﬂects
partly a non-speciﬁc impact of inﬂuenza vaccination on
respiratory mortality in the elderly that is not directly
attributable to inﬂuenza as well as partly a speciﬁc
impact of inﬂuenza vaccination given that analysing
excess mortality necessarily means some truly
inﬂuenza-attributable mortality (ie, that which does not
breach the epidemic threshold) contributes to baseline.
A further possible alternative explanation for the appar-
ent, small inﬂuenza vaccine impact we have observed is
that this is really an impact of pneumococcal vaccin-
ation. This is unlikely to be true; to the end of the
2004/2005 inﬂuenza year, less than 30% of people aged
65 years and over had received the recommended
23-valent pneumococcal polysaccharide vaccine.58
Pneumococcal conjugate vaccination of infants and chil-
dren, which might be expected to provide indirect pro-
tection to the elderly, has only been routinely
recommended since 2006. It is possible that there is
some other factor which also changed over the time
period and which explains part of the mortality impact
we observed (eg, trends in comorbidities linked to
smoking).
Unanswered questions and future research
Inﬂuenza vaccine impact can be difﬁcult to measure
due to its reliance on surveillance data which are gener-
ally not collected in a consistent way over time, and
because of the variable nature of inﬂuenza activity over
time. One way of adding to the evidence base is to look
at vaccine effectiveness. In order to strengthen the evi-
dence base for inﬂuenza vaccine effectiveness in the
elderly, further good-quality cohort and case–control
studies across multiple inﬂuenza seasons with varying
degrees of match between vaccine and circulating var-
iants, as well as adequate control for negative confound-
ing by indication (sicker elderly being preferentially
offered vaccination) and positive confounding by health-
ier older people putting themselves forward for vaccin-
ation, are required. It remains unclear to what extent
our ﬁndings are due to there being less inﬂuenza
around 2000–2005 than before this time or to confound-
ing by factors such as trends in comorbidities linked to
smoking. Analyses including recent inﬂuenza seasons,
which experienced a pandemic (2009/2010) and a
severe inﬂuenza season dominated by the H1N1pdm09
virus (2010/2011) and which saw the vaccine uptake of
the elderly further increase, will help to answer these
questions and to monitor whether the modest mortality
impact we observed in the 6 years after age group-based
targeting of vaccination began has been sustained. This
analysis will be complicated by the presence of pneumo-
coccal vaccination of infants and the elderly, making
teasing apart the effects of how much inﬂuenza
circulated during the time period, the impact of inﬂu-
enza vaccination and the impact of pneumococcal vac-
cination a challenge. A way of addressing this would be
to calculate the attack rates based on serological data
now being collected by HPA CfI.
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